Celyad Oncology SA: Celyad Oncology Announces January 2022 Conference Schedule

Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for

Related Keywords

Mont Saint Guibert ,Waals Gewest ,Belgium ,New York ,United States ,Walloon Region ,Sara Zelkovic ,Filippo Petti ,Hc Wainwright Bioconnect ,Exchange Commission ,Communications Investor Relations ,Lifesci Advisors ,Regulatory News ,Euronext Nasdaq ,Private Securities Litigation Reform Act ,Celyad Oncology ,Annual Report ,Media Contacts ,Investor Relations Director ,Sci Advisors ,Celyad ,Ncology ,Nnounces ,January ,022 ,Conference ,Schedule ,